Correction to: Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the zilver PTX randomized trial (Circulation (2016) 133 (1472-1483) DOI: 10.1161/CIRCULATIONAHA.115.016900);Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial

Circulation

Volumn 133, Issue 15, 2016, Pages 1472-1483

  Dake, Michael D ^a   Ansel, Gary M ^b   Jaff, Michael R ^c   Ohki, Takao ^d   Saxon, Richard R ^e   Smouse, H Bob ^f   Machan, Lindsay S ^g   Snyder, Scott A ^h   O'Leary, Erin E ^h   Ragheb, Anthony O ^h   Zeller, Thomas ⁱ  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RIVERSIDE METHODIST HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JIKEI UNIVERSITY HOSPITAL   (Japan)

^e Tri City Medical Center   (United States)

^f OSF SAINT FRANCIS MEDICAL CENTER   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Cook Medical Inc   (United States)

ⁱ UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

angioplasty; drug eluting stents; paclitaxel; peripheral artery disease; stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE; ANTICOAGULANT AGENT; PACLITAXEL;

AGED; ANKLE BRACHIAL INDEX; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DRUG ELUTING CARDIOVASCULAR STENT; ECHOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FEMORAL ARTERY; FEMOROPOPLITEAL ARTERY DISEASE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STENT FRACTURE; STENT THROMBOSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRASOUND SCANNER; VASCULAR PATENCY; ADULT; ANALOGS AND DERIVATIVES; ANGIOPLASTY; ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICE FAILURE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG ELUTING STENT; INTERMITTENT CLAUDICATION; ISCHEMIA; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; STENT;

ADULT; AGED; ANGIOPLASTY; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; EQUIPMENT FAILURE; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; MALE; MIDDLE AGED; PACLITAXEL; POPLITEAL ARTERY; RECURRENCE; STENTS; TICLOPIDINE; VASCULAR PATENCY;

EID: 84961226396     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000657     Document Type: Erratum

References (34)

1. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, VIVA Physicians, Inc Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007 69 910 919. doi: 10.1002/ccd.21104
2. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E, Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007 115 2745 2749. doi: 10.1161/CIRCULATIONAHA.107.688341
3. Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM, VIBRANT Investigators Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg 2013 58 386 95.e4. doi: 10.1016/j.jvs.2013.01.050
4. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T, Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv 2015 8 1 pt A 102 108. doi: 10.1016/j.jcin.2014.07.023
5. Marmagkiolis K, Hakeem A, Choksi N, Al-Hawwas M, Edupuganti MM, Leesar MA, Cilingiroglu M, 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv 2014 84 555 564. doi: 10.1002/ccd.25510
6. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS, Zilver PTX Investigators Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011 4 495 504. doi: 10.1161/CIRCINTERVENTIONS.111.962324
7. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Snyder SA, O'Leary EE, Tepe G, Scheinert D, Zeller T, Zilver PTX Investigators Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013 61 2417 2427. doi: 10.1016/j.jacc.2013.03.034
8. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, Eschenbach G, Hartmann H, Lange C, Schnorr B, Stiepani H, Zoccai GB, Hänninen EL, Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 2012 5 831 840. doi: 10.1161/CIRCINTERVENTIONS.112.971630
9. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR, IN.PACT SFA Trial Investigators Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015 131 495 502. doi: 10.1161/CIRCULATIONAHA.114.011004
10. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D, LEVANT 2 Investigators Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med 2015 373 145 153. doi: 10.1056/NEJMoa1406235
11. Hamburg NM, Balady GJ, Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation 2011 123 87 97. doi: 10.1161/CIRCULATIONAHA.109.881888
12. Berger JS, Hiatt WR, Medical therapy in peripheral artery disease. Circulation 2012 126 491 500. doi: 10.1161/CIRCULATIONAHA.111.033886
13. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP, Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995 92 614 621
14. Lee EW, Wei LJ, Amato DA, Klein JP, Goel PK, Cox-type regression analysis for large numbers of small groups of correlated failure time observations. Survival Analysis: State of the Art 1992 Dordrecht, Netherlands Kluwer Academic Publishers 237 247. In
15. Sabeti S, Czerwenka-Wenkstetten A, Dick P, Schlager O, Amighi J, Mlekusch I, Mlekusch W, Loewe C, Cejna M, Lammer J, Minar E, Schillinger M, Quality of life after balloon angioplasty versus stent implantation in the superficial femoral artery: findings from a randomized controlled trial. J Endovasc Ther 2007 14 431 437. doi: 10.1583/1545-1550(2007)14[431:QOLABA]2.0.CO;2
16. Chetter IC, Spark JI, Kent PJ, Berridge DC, Scott DJ, Kester RC, Percutaneous transluminal angioplasty for intermittent claudication: evidence on which to base the medicine. Eur J Vasc Endovasc Surg 1998 16 477 484
17. Deutschmann HA, Schoellnast H, Temmel W, Deutschmann M, Schwantzer G, Fritz GA, Brodmann M, Hausegger KA, Endoluminal therapy in patients with peripheral arterial disease: prospective assessment of quality of life in 190 patients. AJR Am J Roentgenol 2007 188 169 175. doi: 10.2214/AJR.05.1408
18. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E, Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006 354 1879 1888. doi: 10.1056/NEJMoa051303
19. Cheng SW, Ting AC, Wong J, Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. Cardiovasc Surg 2001 9 133 140
20. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Bérégi JP, Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005 16 331 338. doi: 10.1097/01.RVI.0000151260.74519.CA
21. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, Lammer J, PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001 12 23 31
22. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, Peeters P, Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011 54 1042 1050. doi: 10.1016/j.jvs.2011.03.272
23. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR, RESILIENT Investigators Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012 19 1 9. doi: 10.1583/11-3627.1
24. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G, 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv 2013 6 282 289. doi: 10.1016/j.jcin.2013.01.128
25. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS, TAXUS IV Investigators Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009 2 1248 1259. doi: 10.1016/j.jcin.2009.10.003
26. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW, Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009 53 1488 1497. doi: 10.1016/j.jacc.2009.01.050
27. Fischer M, Schwabe C, Schulte KL, Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther 2006 13 281 290. doi: 10.1583/05-1799.1
28. Prendiville EJ, Yeager A, O'Donnell TF Jr, Coleman JC, Jaworek A, Callow AD, Mackey WC, Deterling RA, Long-term results with the above-knee popliteal expanded polytetrafluoroethylene graft. J Vasc Surg 1990 11 517 524
29. Green RM, Abbott WM, Matsumoto T, Wheeler JR, Miller N, Veith FJ, Money S, Garrett HE, Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg 2000 31 417 425
30. Ballotta E, Renon L, Toffano M, Da Giau G, Prospective randomized study on bilateral above-knee femoropopliteal revascularization: polytetrafluoroethylene graft versus reversed saphenous vein. J Vasc Surg 2003 38 1051 1055. doi: 10.1016/S0741
31. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR, RESILIENT Investigators Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010 3 267 276. doi: 10.1161/CIRCINTERVENTIONS.109.903468
32. Bosiers M, Torsello G, Gissler HM, Ruef J, Müller-Hülsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroë H, Mathias K, Koppensteiner R, Vermassen F, Scheinert D, Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009 16 261 269. doi: 10.1583/08-2676.1
33. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T, Zilver PTX Single-Arm Study Investigators Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011 18 613 623. doi: 10.1583/11-3560.1
34. Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, Nanto S, O'Leary EE, Lottes AE, Snyder SA, Dake MD, Zilver PTX Post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. JACC. Cardiovasc Interv 2016 9 271 277. doi: 10.1016/j.jcin.2015.09.035